NEW YORK (GenomeWeb) – Belgian diagnostics company MDxHealth reported before the opening of the market on Thursday that its full-year 2016 revenues rose 70 percent, driven by strong growth in its ConfirmMDx prostate cancer test and the launch of its SelectMDx liquid biopsy test.

The company reported total revenues of $30.0 million, up from $17.6 million in 2015. Of the total, US revenues rose 60 percent to $24.4 million from $15.2 million in 2015, and non-US revenues rose 133 percent to $5.6 million from $2.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.